What is the evidence for low-dose aspirin use in primary prevention of cardiovascular disease in patients with type 2 diabetes?
Ogawa et al. conducted a randomized controlled trial to investigate the efficacy of low-dose aspirin in primary prevention of atherosclerotic events in patients with type 2 diabetes. The results of the study showed that low-dose aspirin was effective in reducing the risk of cardiovascular events in this population. Additionally, a systematic review and network meta-analysis by Lotrionte et al. found that low-dose aspirin was the most effective dose and preparation for long-term prevention of cardiovascular disease and cancer.